Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept
暂无分享,去创建一个
S. Sivaprasad | C. Hoyng | J. Garweg | T. Schmelter | O. Sowade | J. Štefanickova | T. Niesen | M. Ophth
[1] P. Kaiser,et al. Intravitreal aflibercept for diabetic macular edema. , 2014, Ophthalmology.
[2] A. Pleil,et al. Psychometric validation of the visual function questionnaire-25 in patients with diabetic macular edema , 2013, Health and Quality of Life Outcomes.
[3] N. Bressler,et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. , 2014, Ophthalmology.
[4] J. Brazier,et al. Evaluating the Relationship Between Visual Acuity and Utilities in Patients With Diabetic Macular Edema Enrolled in Intravitreal Aflibercept Studies. , 2017, Investigative ophthalmology & visual science.
[5] Francesco Bandello,et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. , 2011, Ophthalmology.
[6] A. Mattioli,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[7] J. Leksell,et al. Visual functioning and health-related quality of life in diabetic patients about to undergo anti-vascular endothelial growth factor treatment for sight-threatening macular edema. , 2015, Journal of diabetes and its complications.
[8] S. Rogers,et al. Association Between Diabetes-Related Eye Complications and Symptoms of Anxiety and Depression. , 2016, JAMA ophthalmology.
[9] A. Kampik,et al. [Measuring patient's quality of life in ophthalmology]. , 2003, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.
[10] E. Çelik,et al. Changes in vision related quality of life in patients with diabetic macular edema: ranibizumab or laser treatment? , 2015, Journal of diabetes and its complications.
[11] P. F. Kauff. Group , 2000, Elegant Design.
[12] P. Kaiser,et al. Intravitreal A fl ibercept for Diabetic Macular Edema , 2014 .
[13] Christiane,et al. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.
[14] C. Hirneiss. The impact of a better-seeing eye and a worse-seeing eye on vision-related quality of life , 2014, Clinical ophthalmology.
[15] Gary C. Brown,et al. Update on Value-Based Medicine , 2013, Current opinion in ophthalmology.
[16] P. Kaiser,et al. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. , 2015, Ophthalmology.
[17] A. Pleil,et al. Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham. , 2011, Investigative ophthalmology & visual science.
[18] E. Lamoureux,et al. Vision-Related Quality of Life Outcomes in the BEVORDEX Study: A Clinical Trial Comparing Ozurdex Sustained Release Dexamethasone Intravitreal Implant and Bevacizumab Treatment for Diabetic Macular Edema. , 2016, Investigative ophthalmology & visual science.
[19] N. Bressler,et al. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. , 2012, Ophthalmology.
[20] P. Romero-Aroca,et al. What Is the Role of Retinal Barriers in Diabetic Macular Edema ? , 2016 .
[21] Roberta McKean-Cowdin,et al. Severity of diabetic retinopathy and health-related quality of life: the Los Angeles Latino Eye Study. , 2011, Ophthalmology.
[22] P. Kaiser,et al. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. , 2016, Ophthalmology.
[23] Prevalence of diabetic retinopathy and cataract in adult patients with type 1 and type 2 diabetes in Russia. , 2009, The review of diabetic studies : RDS.
[24] P. Romero-Aroca. Targeting the Pathophysiology of Diabetic Macular Edema , 2010, Diabetes Care.